---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-021229"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2026-01-23T23:59:59+00:00"
generated_at: "2026-05-16T08:23:12.923499+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Soleno Therapeutics approves FY2026 salary hikes, FY2025 bonuses, equity grants, and new severance plan for NEOs

## Summary
- CEO base salary raised to $765k; CFO to $529k; CCO to $515k; SVP Regulatory to $447k.
- FY2025 cash bonuses: CEO $487,740; CFO $218,708; CCO $201,588; SVP Reg $161,784.
- CEO granted 131,400 stock options and 114,200 RSUs; other NEOs received smaller awards.
- New Key Executive Change in Control/Severance Plan offers up to 24 months salary + 150% target bonus + full equity acceleration in change-in-control event.
- Outside a change-in-control, CEO gets 18 months salary, 100% target bonus, and 25% equity acceleration; other execs get 9-12 months with no equity acceleration.

## SEC filing metadata
- accession: 0001193125-26-021229
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2026-01-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312526021229/0001193125-26-021229-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312526021229/d93569d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-021229
- JSON: https://secwatch.observer/filing/0001193125-26-021229.json
- Plain text: https://secwatch.observer/filing/0001193125-26-021229.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.